[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"iOMEDICO AG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":410},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,40,66,95,113,133,160,180,206,233,244,273,303,312,337,360,382],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100054080","myeloma-registry-platform-myriam-100054080",false,"NCT03308474","Myeloma Registry Platform (MYRIAM)","Clinical Research Platform for Molecular Testing, Treatment and Outcome of Patients With Multiple Myeloma (Myeloma Registry Platform; MYRIAM)","MYRIAM","Inclusion Criteria:\n\n* MM requiring systemic (first-, second- or third-line) treatment (closed for first-line \u002F second-line recruitment)\n* Age ≥ 18 years\n* Written informed consent\n\n  * Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment\n  * Patients not participating in the PRO satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment\n* Sufficient German language skills for participation in the PRO satellite\n\nExclusion Criteria:\n\n* No systemic therapy for myeloma\n* Patients already enrolled in studies that prohibit any participation in other studies","ALL","18 Years",{"count":20,"type":21},2200,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.",[26],"Multiple Myeloma","RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2017-09-25",{"date":35,"type":21},"2028-12",{"name":37,"class":38},"iOMEDICO AG","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":50,"conditions":51,"keywords":58,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100053791","registry-platform-hematologic-malignancies-rubin---extension-of-tumor-registry-lymphatic-neoplasms-100053791","NCT06043011","Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","RUBIN","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed diagnosis of the respective NHL\n* If patient is alive: signed written informed consent\n\n  * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.\n  * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.\n\nExclusion Criteria:\n\n* No systemic therapy for respective lymphoid malignancy.",{"count":49,"type":21},2950,"The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.",[52,53,54,55,56,57],"Chronic Lymphocytic Leukemia (CLL)","Diffuse Large B-cell Lymphoma (DLBCL)","Follicular Lymphoma (FL)","Mantle Cell Lymphoma (MCL)","Marginal Zone Lymphoma (MZL)","Waldenström's Macroglobulinemia (WM)",[59],"non-Hodgkin lymphoma (NHL)",{"date":30,"type":31},{"date":62,"type":31},"2023-09-27",{"date":64,"type":21},"2033-12",{"name":37,"class":38},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":74,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100636277","elacestrant-in-patients-with-er-her2--esr1-mutated-locally-advanced-or-metastatic-breast-cancer-100636277","NCT07563595","Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer","Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer: a Multicenter, National, Prospective Non-interventional Study","ELENI","Inclusion Criteria:\n\n* Signed and dated informed consent form\n* Postmenopausal women\n* Age ≥18 years\n* Eastern Cooperative Oncology Group Performance Status (ECOG) \\\u003C 2\n* Locally advanced and\u002For metastatic ER+ HER2- breast cancer\n* Histologically proven ER positivity (defined as ≥1% staining by immunohistochemistry (IHC))\n* Histologically proven HER2 negativity (defined as a IHC0 or IHC1+ score by IHC or a negative result by in situ hybridization (ISH), optionally combined with a IHC2+ score)\n* Disease progression following first line ET + CDKi\n* No more than one prior ET line in the advanced\u002Fmetastatic setting and intention for 2nd-line treatment with elacestrant according to current elacestrant SmPC as assessed by the treating physician (ESR1 testing can be done after inclusion)\n* For patients with proven ESR1mut: Study inclusion the latest 2 weeks after start of elacestrant treatment\n\nExclusion Criteria\n\n* Prior chemotherapy in the advanced\u002Fmetastatic setting\n* Contraindications according to elacestrant SmPC, except for ESR1 test result for patients included prior to ESR1 testing.\n* Participation in an interventional clinical trial within 30 days prior to enrolment or simultaneous participation in an interventional clinical trial (except follow-up phase)","FEMALE",{"count":76,"type":21},500,"The objective of this non-interventional study (NIS) is to evaluate prevalence of ESR1 mutation after endocrine therapy in the palliative setting, quality of life, tolerability, and safety and to describe treatment detail and adverse event (AE) management in postmenopausal women with locally advanced and\u002For metastatic ER+ HER2- ESR1-mutated breast cancer and second line treatment with elacestrant according to SmPC (Summary of product characteristics) in a real-world setting.",[79],"Breast Cancer",[81,82,83,84,85],"Elacestrant","advanced breast cancer","Quality of life","ESR1 Mutation","Orserdu","2026-06-24",{"date":88,"type":31},"2026-06-25",{"date":90,"type":31},"2026-06-19",{"date":92,"type":21},"2028-06",{"name":37,"class":38},3,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":39},"100635985","a-non-interventional-study-of-melphalan-flufenamide-melflufen-pepaxti-and-dexamethasone-in-patients-with-relapsed-andor-refractory-multiple-myeloma-rrmm-100635985","NCT07559799","A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and\u002For Refractory Multiple Myeloma (R\u002FRMM)","MARINA","Inclusion Criteria:\n\n* Patients with R\u002FRMM who have previously been treated with at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who relapsed on or after the last therapy\n* Indication and decision for fourth- or later-line treatment with melflufen (Pepaxti®) and dexamethasone, according to current SmPC as assessed by the treating physician\n* Signed and dated written informed consent\\*.\n* Treatment decision before inclusion into this non-interventional study\n* Age ≥18 years\n\n  * Patients are allowed to be enrolled up to 28 days (+ 14 days) after their first dose of melflufen+dexamethasone,, but before any response assessment and second dose of melflufen+dexamethasone. These patients will not participate in the PRO assessments.\n\nExclusion Criteria:\n\n* Participation in an interventional clinical trial (except follow-up)\n* Patient unable to consent\n* Contraindications according to current SmPC",{"count":103,"type":21},50,"Multiple myeloma is the second most common hematologic malignancy in adults and despite the new therapies that have been developed in the last decades it remains incurable. Over the course of the disease, patients eventually become refractory to the various treatments. Therefore, new therapeutic options which utilize new mechanisms of action are essential.\n\nMelphalan flufenamide (melflufen) represents such an additional therapeutic approach. Melflufen is a peptide-drug conjugate (PDC) which is highly lipophilic and rapidly incorporated into the tumor cells. Once inside the tumor cell, melflufen is hydrolyzed by peptidases, including aminopeptidases and esterases, to release its alkylator payload. The alkylating agent then induces DNA damage resulting in cell death.\n\nMelphalan flufenamid in combination with Dexamethason was approved by the European Medicines Agency (EMA) in August 2022 for the treatment of patients with triple class refractory relapsed\u002Frefractory Multiple Myeloma who have received at least 3 prior lines of therapy. For patients with prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.\n\nThe non-interventional study MARINA aims to address open scientific questions regarding the effectiveness, as well as therapy and safety management of melflufen in a real-world setting. By collecting comprehensive real-world data - including the Disease Control Rate (DCR) as a key endpoint, which is of most value for patients in this late disease stage - MARINA will investigate the therapeutic benefit of melflufen in routine clinical practice.",[26],{"date":107,"type":31},"2026-06-26",{"date":109,"type":31},"2026-06-01",{"date":111,"type":21},"2029-08-30",{"name":37,"class":38},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},"100562756","ivosidenib-in-locally-advanced-or-metastatic-cholangiocarcinoma-with-idh1-r132-mutation-after-at-least-one-prior-systemic-treatment---an-observational-study-100562756","NCT06607302","Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study","Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - a Prospective, Multicenter, Observational Study in Germany","IDHIRA","Inclusion Criteria:\n\n* Age 18 years or older.\n* Histologically confirmed locally advanced or metastatic CCC with a documented IDH1 R132 mutation diagnosed by an appropriate diagnostic test\n* Patients must have at least one prior systemic therapy\n* Decision for treatment with ivosidenib according to current SmPC.\n* Signed written informed consent before or within 6 weeks of first ivosidenib dose (inclusion of patients up to 6 weeks after first ivosidenib intake is allowed for patients not participating in the PRO module)\n* For patients participating in the PRO module (optional):\n\n  * Dated signature of informed consent form before start of study treatment.\n  * Willingness and capability to participate in PRO assessment in German language.\n* Other criteria according to current SmPC.\n\nExclusion Criteria:\n\n* Participation in an interventional clinical trial within 30 days prior to enrolment or concurrent participation in an interventional clinical trial except for the follow-up period.\n* Other contraindications according to current SmPC.",{"count":122,"type":21},100,"Cholangiocarcinoma is a rare and aggressive tumor of the bile duct associated with a poor prognosis and very limited treatment options. The IDH1 inhibitor ivosidenib provides a new, targeted treatment option for this disease. Ivosidenib was approved by European Medicines Agency (EMA) in May 2023 as monotherapy in adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.\n\nThe prospective, multicenter, observational study IDHIRA will collect first real-world data on ivosidenib treatment in a broad patient population in Germany. Ivosidenib will be administered according to the current SmPC. Thus, IDHIRA will generate real-world evidence on effectiveness, quality of life (QoL) and safety of ivosidenib.",[125],"Cholangiocarcinoma",{"date":88,"type":31},{"date":128,"type":31},"2024-10-08",{"date":130,"type":21},"2027-12",{"name":37,"class":38},13,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":39},"100591168","research-platform-myelofibrosis-and-anemia-100591168","NCT06976918","Research Platform Myelofibrosis and Anemia","Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Primary and Secondary Myelofibrosis and Anemia Who Are JAK Inhibitor Treatment-naïve or JAK Inhibitor Treatment-experienced (RHODOLITE)","RHODOLITE","Inclusion Criteria:\n\n* Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively).\n* Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician.\n* Start of first or subsequent systemic treatment for MF.\n* Informed consent and registration for the GSG-MPN Bioregistry.\n* Willingness and capability to participate in PRO assessment.\n* Signed and dated informed consent form for RHODOLITE at the latest six weeks after start of the respective systemic MF treatment.\n\nExclusion Criteria:\n\n* No systemic therapy for diagnosed primary or secondary MF.\n* Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.",{"count":142,"type":21},200,"The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease and to collect patient-reported outcomes for patients with primary and secondary myelofibrosis and anemia in Germany.",[145,146,147,148,149,150,151],"Primary Myelofibrosis","Secondary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","Anemia","Myelofibrosis; Anemia","Myelofibrosis","2026-06-03",{"date":154,"type":31},"2026-06-05",{"date":156,"type":31},"2026-02-19",{"date":158,"type":21},"2031-09",{"name":37,"class":38},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":170,"studyType":23,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":179,"locationsCount":39},"100401706","liver-cancer-registry-platform-100401706","NCT04510740","Liver Cancer Registry Platform","JADE - Clinical Research Platform on Treatment and Outcome in Patients With Hepatocellular or Cholangiocellular Cancer","JADE","Inclusion criteria:\n\n* Confirmed hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCC) als early, intermediate or advanced\u002Fmetastatic stage\n* Age ≥ 18 years\n* Signed and dated informed consent (IC):\n\n  * For participation in the PRO module: Before primary locoregional therapy or start of first systemic treatment\n  * For no participation in the PRO module: No later than 8 weeks after primary locoregional therapy or start of first systemic treatment\n\nExclusion criteria:\n\nPatients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)",{"count":169,"type":21},1000,"3 Years","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.",[173,125],"Hepatocellular Carcinoma (HCC)",{"date":175,"type":31},"2026-06-04",{"date":177,"type":31},"2020-08-09",{"date":130,"type":21},{"name":37,"class":38},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":39},"100317781","breast-cancer-registry-platform-100317781","NCT03417115","Breast Cancer Registry Platform","Treatment and Outcome of Patients With Breast Cancer: Clinical Research Platform for Real World Data","OPAL","EBC cohort:\n\n* Female and male patients with early breast cancer (stage I-III defined as breast cancer that has not spread beyond the breast or the axillary lymph nodes)\n* Patients at the start of their initial systemic treatment for EBC, i.e. at start of neoadjuvant treatment for patients receiving neoadjuvant therapy or at start of adjuvant treatment if no neoadjuvant therapy is given. Treatment can be cytotoxic, endocrine, or targeted substances, whatever was given first\n\nABC cohort I (prospective):\n\n* Female and male patients with advanced breast cancer (stage IV defined as synchrone or metachrone diagnosis of distant metastases at inclusion)\n* Patients at the start of their initial first-line systemic treatment for ABC, which can be cytotoxic, endocrine or targeting a specific signaling pathway, whatever is given first\n\nABC cohort II (retrospective):\n\n* Confirmed diagnosis of HR-positive, HER2-negative ABC (stage IV defined as synchrone or metachrone diagnosis of distant metastases at inclusion)\n* Start of initial first-line systemic treatment for ABC, which can be cytotoxic, endocrine or targeting a specific signaling pathway, whatever is given first, between September 2021 and December 2025\n* Inclusion is possible regardless of whether patients are alive or deceased at the time of documentation; for patients alive: written informed consent\n\nProspective cohorts:\n\n* Written informed consent\n* Patients participating in the PRO module: signing of informed consent form and completion of baseline questionnaire before start of initial systemic treatment for EBC or systemic first-line treatment for ABC\n* All patients not participating in the PRO module: within six weeks after start of initial systemic treatment for EBC or systemic first-line treatment for ABC\n\nAll cohorts:\n\n• Age ≥ 18 years",{"count":189,"type":21},6150,"The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with breast cancer in Germany.",[79],[79,193,194,195,196,197,198,199],"Epidemiology","Registry","Health Services Research","Germany","Palliative Treatment","Adjuvant Treatment","Neoadjuvant Treatment",{"date":154,"type":31},{"date":202,"type":31},"2017-12-22",{"date":204,"type":21},"2032-06",{"name":37,"class":38},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":232,"locationsCount":39},"100576577","fruquintinib-in-patients-with-metastatic-colorectal-cancer-100576577","NCT06787105","Fruquintinib in Patients With Metastatic Colorectal Cancer","Fruquintinib in Patients With Metastatic Colorectal Cancer: A Prospective, Multicenter, Observational Study","FRUQUENT","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Indication and decision for therapy with fruquintinib in accordance with the current German SmPC of fruquintinib as monotherapy for patients with mCRC.\n* Prior treatment with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF therapy, and if RAS wild-type, anti EGFR therapy.\n* Progression on or intolerance to treatment with either trifluridine\u002Ftipiracil and\u002For regorafenib.\n* Other criteria according to current SmPC.\n* Signed written informed consent.\\* \\* Patients are allowed to be enrolled up to 6 weeks after their first dose of fruquintinib. These patients cannot participate in the PRO assessments.\n\nExclusion Criteria:\n\n* Participation in an interventional clinical trial (except follow-up) within 30 days prior to enrollment or start of treatment with fruquintinib, whatever comes first.\n* Contraindications according to current SmPC.",{"count":215,"type":21},150,"FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard therapies.\n\nTo this end, it will be analyzed how well patients respond to the therapy in the clinical routine. Further points of interest to the study are survival data, safety data, the use of medical care facilities, and the quality of life of patients treated with Fruquintinib.\n\nParticipants will be treated as decided by the treating physician and according to their routine practice.\n\nFRUQUENT is accompanied by a translational research project combining real-world clinical data with foundational research to stratify patient collectives in regards to the therapeutic benefit of fruquintinib.",[218],"Metastatic Colorectal Cancer (mCRC)",[220,221,222,223,224,225],"non-interventional","Fruzaqla","electronic QoL questionnaire","Real-world disease control rate","Later line","Fruquintinib","2026-03-31",{"date":228,"type":31},"2026-04-06",{"date":230,"type":31},"2025-02-17",{"date":130,"type":21},{"name":37,"class":38},{"id":234,"slug":4,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":235,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":50,"conditions":236,"keywords":237,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":243,"locationsCount":39},"100519397",{"count":49,"type":21},[52,53,54,55,56,57],[59],"2026-01-26",{"date":240,"type":31},"2026-01-28",{"date":62,"type":31},{"date":64,"type":21},{"name":37,"class":38},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":74,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":170,"studyType":23,"phases":4,"briefSummary":254,"conditions":255,"keywords":263,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":39},"100449245","registry-platform-ovarian-and-endometrial-cancer-100449245","NCT05129969","Registry Platform Ovarian and Endometrial Cancer","SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes","SMARAGD","Inclusion Criteria:\n\n* Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):\n\n  * patients with FIGO stage IIb-IV OC who are starting systemic treatment or\n  * patients with recurrent\u002Frelapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent\u002Frelapsed disease.\n* Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.\n* Signed and dated informed consent (IC):\n\n  * Patients participating in PRO module: IC before first therapy cycle\n  * Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle\n\nExclusion Criteria:\n\n* newly diagnosed early-stage OC (FIGO stage I-IIa)\n* Low grade mOC OR\n* Early-stage EC (FIGO stage I-II)",{"count":253,"type":21},1975,"The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.",[256,257,258,259,260,261,262],"Ovarian Cancer","Endometrial Cancer","Ovary Neoplasm","Endometrial Neoplasms","Carcinoma, Ovarian","Carcinoma","Neoplasm, Ovarian",[194,264,193,196,265,266],"Health service research","Palliative treatment","Palliative care",{"date":240,"type":31},{"date":269,"type":31},"2021-11-25",{"date":271,"type":21},"2030-12",{"name":37,"class":38},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":283,"studyType":23,"phases":4,"briefSummary":284,"conditions":285,"keywords":290,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":39},"100384830","registry-platform-gastricesophageal-cancer-saphir-100384830","NCT04290806","Registry Platform Gastric\u002FEsophageal Cancer (SAPHIR)","Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy","SAPHIR","Inclusion Criteria:\n\n* Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC\n* Planned palliative systemic first-line therapy\n* Age \\>= 18 years\n* Signed informed consent (IC)\n\n  * Patients answering questionnaires: IC before first therapy cycle\n  * Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle\n\nExclusion Criteria:\n\n* No systemic therapy for ESCC, EAC, GAC or GEJAC",{"count":282,"type":21},1900,"2 Years","The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.",[286,287,288,289],"Esophageal Squamous Cell Carcinoma","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma",[291,292,293,294,196,295,296],"neoplasms","registry","health services research","epidemiology","palliative treatment","palliative care",{"date":240,"type":31},{"date":299,"type":31},"2019-12-04",{"date":301,"type":21},"2028-12-31",{"name":37,"class":38},{"id":304,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":305,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":306,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":310,"leadSponsor":311,"locationsCount":39},"100309448",{"count":20,"type":21},[26],{"date":308,"type":31},"2026-01-27",{"date":33,"type":31},{"date":35,"type":21},{"name":37,"class":38},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":39},"100573188","ropeginterferon-alfa-2b-in-patients-with-polycythemia-vera-pv-without-symptomatic-splenomegaly-100573188","NCT06743035","Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly","Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly: A Prospective, Longitudinal, Multicenter, Observational Study in Germany","ROPE","Inclusion Criteria:\n\n* Age ≥18 years\n* Confirmed diagnosis of PV without symptomatic splenomegaly\n* Indication and decision for treatment with ropeginterferon alfa-2b in accordance with current SmPC\n* No prior treatment with ropeginterferon alfa-2b (Patients are allowed to be enrolled up to 6 weeks after their first dose of ropeginterferon alfa-2b but must still be on treatment at the time of enrollment.)\n* Dated signature of informed consent form\n* Participation in Patient-Reported Outcome (PRO) assessment in German language and completion of questionnaire at time of study enrollment\n* Other criteria according to current Summary of Product Characteristics\n\nExclusion Criteria:\n\n* Participation in an interventional clinical trial (except follow-up)\n* Other contraindications according to current Summary of Product Characteristics",{"count":142,"type":21},"The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. Further patient-relevant endpoints include effectiveness including complete hematologic response (CHR), event-free survival (EFS), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.",[323],"Polycythemia Vera",[325,326,327,328],"Ropeginterferon alfa-2b","polycythemia vera","symptom burden","myeloproliferative neoplasm","2026-01-08",{"date":331,"type":31},"2026-01-09",{"date":333,"type":31},"2024-12-03",{"date":335,"type":21},"2029-07",{"name":37,"class":38},{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":39},"100611444","vorasidenib-in-cns-who-grade-2-idh-mutant-diffuse-glioma-100611444","NCT07240662","Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma","Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma: A Multicenter, Prospective, Non-interventional Study in Germany","VIOLETA","Inclusion Criteria:\n\n* Age ≥18 years\n* WHO grade 2 astrocytoma or oligodendroglioma\n* Presence of IDH1- or IDH2-mutation\n* Surgical intervention\n* No immediate need of radiotherapy or chemotherapy according to the treating physician\n* Decision for treatment with vorasidenib as per current SmPC\n* Signed written informed consent\\*\n* Willingness to participate in Patient-Reported Outcome (PRO) assessment in German language\n* Other criteria according to current SmPC \\* Patients are allowed to be enrolled up to 6 weeks after their first intake of vorasidenib but must still be on treatment at the time of enrollment\n\nExclusion Criteria:\n\n* Participation in an interventional clinical trial\n* Patient unable to consent\n* Other contraindications according to current SmPC.",{"count":215,"type":21},"The goal of this prospective, observational study VIOLETA is to collect real-world data on vorasidenib treatment in a broad patient population. Though vorasidenib can be administered from 12 years old, VIOLETA focuses on adult patients with IDH1- or IDH2-mutant WHO grade 2 glioma who receive vorasidenib following surgery according to the current SmPC. Thus, VIOLETA will evaluate for the first-time treatment with vorasidenib in German clinical routine. To gain knowledge about how vorasidenib treatment affects patients' well-being, the primary objective of the study is to assess patients' quality of life. Further patient-relevant endpoints addressed by this study will include seizure burden, PFS, Objective Response Rate (ORR), TTNI, safety as well as factors affecting treatment decision making.",[348],"Glioma",[350,351,352],"WHO Grade 2","IDH-mutant","diffuse","2026-01-07",{"date":331,"type":31},{"date":356,"type":31},"2025-12-08",{"date":358,"type":21},"2032-01",{"name":37,"class":38},{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":170,"studyType":23,"phases":4,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":39},"100314496","registry-platform-urologic-cancer-100314496","NCT03374267","Registry Platform Urologic Cancer","Clinical Research Platform On Urologic Cancer Treatment And Outcome (Registry Platform Urologic Cancer; CARAT)","CARAT","Inclusion Criteria:\n\nCohorts aRCC and aUBC (prospective)\n\n* Female and male patients with aRCC or aUBC (locally advanced, inoperable or metastatic)\n* Patients at start of their first-line systemic treatment for aRCC or aUBC\n* Written informed consent\n\n  * Patients participating in the PRO module: signing of in-formed consent form and completion of baseline questionnaire before start of initial systemic treatment\n  * Patients not participating in the PRO module: within twelve weeks after start of systemic first-line for aRCC or aUBC\n* Age ≥ 18 years\n\nCohort High-risk MIUC (prospective and retrospective)\n\n* Histologically proven muscle-invasive urothelial carcinoma (MIUC) of the lower or upper urinary tract (ICD-10 C65, C66, C67.x, C68.x). Mixed histologies are allowed (main compo-nent must be urothelial carcinoma, with minor variants accept-ed).\n* Radical surgery (e.g., radical cystectomy, nephroureterecto-my) between October 1, 2021 and October 31, 2024.\n* High-risk of recurrence, defined as follows: Post-operative, pathological tumor status\n\n  * ypT2-ypT4 and\u002For ypN+ and without clinically detectable metastases (M0) at cystectomy for patients with prior neo-adjuvant chemotherapy or\n  * pT3-pT4 and\u002For pN+ and without clinically detectable me-tastases (M0) at cystectomy for patients without prior neo-adjuvant chemotherapy.\n* Age ≥ 18 years at the time of surgery.\n* Written informed consent (only if patient is alive at time of data entry; not applicable for inclusion of deceased patients' data)\n\nExclusion Criteria:\n\nCohorts aRCC and aUBC (prospective)\n\n* Patients with prior systemic therapy for aRCC or aUBC\n* No systemic treatment for aRCC or aUBC\n\nCohort High-risk MIUC (prospective and retrospective)\n\n* Partial cystectomy or partial nephrectomy of the primary tumor as definitive therapy\n* Metastatic disease (M1) at the time of surgery",{"count":369,"type":21},1930,"The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced renal cell carcinoma or urothelial cancer in Germany.",[372,373],"Renal Cell Carcinoma","Urothelial Carcinoma","2025-09-19",{"date":376,"type":31},"2025-09-22",{"date":378,"type":31},"2017-12-07",{"date":380,"type":21},"2028-09",{"name":37,"class":38},{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":392,"conditions":393,"keywords":398,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":409},"100464331","zanubrutinib-in-patients-with-waldenstrms-macroglobulinemia-chronic-lymphocytic-leukemia-marginal-zone-lymphoma-and-follicular-lymphoma-100464331","NCT05326308","Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma","Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL) - a Prospective Multicenter Observational Cohort Study","ARIADNE","Inclusion Criteria:\n\n* Waldenström's macroglobulinemia (all treatment lines) OR\n* Chronic lymphocytic leukemia (all treatment lines) OR\n* Marginal zone lymphoma (≥2 treatment line and at least one anti-CD20 antibody-based previous therapy)\n* Follicular lymphoma (≥3 treatment line)\n* Signed and dated informed consent form\n* Treatment with zanubrutinib according to current SmPC for WM, CLL and MZL\n* Treatment with zanubrutinib + obinutuzumab for FL according to current SmPC\n* Treatment decision before inclusion into this non-interventional study\n* Age ≥18 years.\n\nExclusion Criteria:\n\n* Contraindications according to SmPC for patients with WM, CLL, MZL or FL\n* Participation in an interventional clinical trial during zanubrutinib treatment.",{"count":391,"type":21},705,"The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.",[394,395,396,397],"Waldenström's Macroglobulinemia","Chronic Lymphocytic Leukemia","Marginal Zone Lymphoma","Follicular Lymphoma",[394,399,400,395,396,397],"Zanubrutinib","Brukinsa","2025-09-18",{"date":403,"type":31},"2025-09-23",{"date":405,"type":31},"2022-04-26",{"date":407,"type":21},"2028-08",{"name":37,"class":38},2,""]